Tag Archive for: R1 Therapeutics

Weekly Roundup: With great power comes a place on the Medicine Maker Power List. Optimum’s clients have the power.

/in

ReBio Pharma appointed leading ocular oncologist Professor Mandeep Sagoo as Chief Medical Officer ReBio Pharma, a biotechnology company developing novel, targeted, eye- and vision-preserving therapies for ocular oncology, announced the appointment of Professor Mandeep Sagoo, MB, PhD, FRCS (Ed), FRCOphth, as Chief Medical Officer (CMO). In this role, Professor Sagoo will lead ReBio’s clinical and […]

Read more

R1 Therapeutics announces commencement of global Phase 2b trial of AP306 for hyperphosphatemia in patients on dialysis

/in

AP306 is a first-in-class pan phosphate transporter inhibitor in development as a monotherapy for hyperphosphatemia, a near-universal and serious complication in chronic kidney disease patients Study underway with first patient randomized in the global Phase 2b trial of AP306 conducted in partnership with Alebund in the US and China Study builds on positive Phase 2a […]

Read more

Weekly Roundup: The latest in first-in-class biotech and medtech

/in

Hansa Biopharma announced the closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA Hansa Biopharma AB and SERB S.A. announced that the required regulatory approvals have been obtained and that the previously announced €115 million exclusive licensing transaction with SERB has closed. The company also announced that Maria Törnsén, […]

Read more

R1 Therapeutics establishes world-class Scientific Advisory Board to support advancement of AP306 in Chronic Kidney Disease

/in

Seven internationally recognized nephrology experts join R1’s Scientific Advisory Board Strengthens scientific and clinical guidance as AP306 advances into global Phase 2b development for the treatment of hyperphosphatemia in chronic kidney disease Board chaired by Glenn M. Chertow, M.D., MPH, Professor of Medicine, Epidemiology and Population Health, and Health Policy at Stanford University School of […]

Read more

Weekly Roundup: Appointments and new perspectives

/in

Hansa Biopharma appointed Adam Cutler as new Chief Financial Officer Hansa Biopharma AB announced the appointment of Adam Cutler as its new Chief Financial Officer (CFO) and member of the Executive Committee, effective June 22, 2026.  Adam succeeds Evan Ballantyne, who has served as CFO since 2024. Evan will continue in the role until June […]

Read more
© Optimum Strategic Communications.